CRMD · XBRL financial data

CorMedix financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CRMD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	239	191	65	—	43,472	311,709
Cost of revenue	205	149	4	—	3,191	22,089
Gross profit	34	42	62	—	40,282	275,748
Research and development	13,377	13,133	10,680	13,155	3,942	19,333
Selling, general and administrative	13,878	16,347	20,006	35,803	—	—
General and administrative	—	—	—	17,687	29,959	68,220
Total operating expenses	27,255	29,480	30,686	48,958	62,638	125,607
Operating income (loss)	(27,221)	(29,438)	(30,624)	(48,958)	(22,356)	150,141
Interest income	116	—	—	2,682	2,579	3,846
Interest expense	33	16	27	34	36	2,782
Other income (expense)	24	(23)	337	2,619	—	—
Income tax expense (benefit)	(5,169)	(1,250)	(586)	—	(1,395)	(13,039)
Net income (loss)	(22,028)	(28,210)	(29,702)	(46,339)	(17,930)	163,055
Earnings per share, basic USD per share	—	(0.75)	(0.74)	(0.91)	(0.30)	2.25
Earnings per share, diluted USD per share	—	(0.75)	(0.74)	(0.91)	(0.30)	2.04
Weighted average shares, basic thousands of shares	—	37,666	40,274	50,903	58,872	72
Weighted average shares, diluted thousands of shares	—	37,666	40,274	50,903	58,872	80

Fiscal years (CRMD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	41,905	53,317	43,148	43,643	40,651	144,837
Short-term investments	4,444	12,149	15,644	32,388	11,037	3,694
Marketable securities	—	—	—	—	—	10,364
Accounts receivable	—	—	—	—	51,654	171,233
Inventory	144	3	—	2,106	7,600	29,716
Prepaid and other current assets	1,412	770	624	882	3,482	17,571
Total current assets	48,182	66,469	59,551	79,450	114,575	367,051
Property and equipment, net	111	1,475	1,610	1,866	1,828	5,959
Right-of-use asset	1,015	900	775	640	493	3,020
Goodwill	—	—	—	—	—	30,002
Total assets	49,308	68,946	62,038	82,060	118,846	826,142
Accounts payable	1,128	2,210	2,202	4,280	1,720	7,884
Accrued liabilities	2,924	3,014	3,974	6,970	31,952	161,921
Total current liabilities	4,162	5,345	6,311	11,401	33,840	174,269
Lease liability, non-current	924	802	668	517	349	2,253
Total liabilities	5,085	6,148	6,979	11,918	34,189	420,835
Accumulated deficit	(217,449)	(245,659)	(275,361)	(321,700)	(339,630)	(176,575)
Total stockholders' equity	44,223	62,798	55,060	70,142	84,657	405,307
Total liabilities and equity	49,308	68,946	62,038	82,060	118,846	826,142
Common shares outstanding (cover page) thousands of shares	38,024	38,728	44,500	54,981	65,182	79,050

Fiscal years (CRMD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(22,028)	(28,210)	(29,702)	(46,339)	(17,930)	163,055
Stock-based compensation	2,500	5,043	4,070	5,494	6,129	13,832
Net cash from operating activities	(21,968)	(21,155)	(24,357)	(38,409)	(50,615)	175,046
Purchases of property and equipment	113	1,425	219	327	116	2,260
Net cash from investing activities	7,426	(9,135)	(3,709)	(17,062)	21,231	(308,430)
Proceeds from issuing common stock	18,433	41,456	17,770	12,949	18,882	7,788
Net cash from financing activities	40,100	41,758	17,898	55,917	26,319	238,453
Net change in cash	25,572	11,454	(10,177)	448	(3,067)	105,069

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
CorMedix	256,692	101,931	86,237*	77.9M	—	Q2 FY26 10-QJun 30, 2026
Ardelyx	46,317	127,655	2,171*	251.4M	—	Q3 FY26 10-QSep 30, 2026
Collegium Pharmaceutical	129,467	199,878	71,323*	32.6M	—	Q2 FY26 10-QJun 30, 2026
Viridian Therapeutics	172,860	25,752	(92,773)*	113.6M	9.0 quarters	Q3 FY26 10-QSep 30, 2026
Akebia Therapeutics	155,548	49,128	3,525*	277.1M	—	Q2 FY26 10-QJun 30, 2026
Intellia Therapeutics	106,128	7,659	(83,113)*	140.1M	5.3 quarters	Q2 FY26 10-QJun 30, 2026
Geron	62,643	57,480	(15,827)*	642.5M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
Neogen	172,000	222,800	12,900	218.3M	—	Q1 FY27 10-QAug 31, 2026
Wave Life Sciences	197,315	13,158	(60,142)*	197.2M	7.4 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.